ALSO NOTED: Lilly wins patent fight; Canada OKs Tarceva; Vioxx trial begins; and much more...

> A US appeals court has upheld Eli Lilly's patent on Sarafem for premenstrual stress. Teva had challenged the patent saying it is an exact copy of Prozac, which is no longer under patent protection. Report

> Cryocor has priced its IPO at $11 per share. Report

> Canadian regulators have approved OSI's Tarceva for lung cancer. Report

> The first trial of Vioxx is set to begin after a jury was selected in the small Texas town of Angleton. Story

> Merck has acquired most of the global rights for the cancer treatment UFT for the treatment of colorectal cancer from Taiho Pharmaceutical. Release

> Acambis has launched a Phase II trial of a weakened smallpox vaccine for patients unable to take a full dose. Report

> The FDA has approved Ranbaxy's anti-retroviral drug Zidovudine for use outside the US. Story

And Finally... Scientists report that they have discovered a simple therapy to reduce the high risk of death from SARS. Article

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.